Başka bir renk deneyin:
Başka bir font büyüklüğü deneyin: 60% 70% 80% 90%


 


ULUSLARARASI ŞEFFAFLIK KOMİTESİNİN İLAÇ SEKTÖRÜ 2016 RAPORU:

CORRUPTION IN THE PHARMACEUTICAL SECTOR (İLAÇ SEKTÖRÜNDEKİ YOLSUZLUKLAR)

• A lack of objective data and understanding of corruption inhibited by environmental context, the complexity of issues in the sector and policy makers not viewing corruption as an issue.
• A weak legislative and regulatory framework because of poor investment, a lack of oversight and national regulatory frameworks that are often decentralised and reliant on self-regulation for key decision-point.
• The potential for undue influence from companies due to a high degree of autonomy over key decision points and unparalleled resources, on policy and regulation so profit maximisation goes beyond ethical norms and negatively impacts health outcomes and public health objectives.
• A lack of leadership committed to anti-corruption efforts from all actors. National leaders often only implement reforms after a crisis, with their inaction regularly hindering other actors.